Business Wire

CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting

CLL is the most common type of leukemia in adults. 3 An estimated 18,500 people were treated for CLL in the 1st-line setting in the US in 2024. 4 Jennifer Brown, MD, PhD, Director of the CLL Center of ...
STAT

As targeted therapies prevail, patient voice and preference should, too

Cancer patients want to beat cancer, full stop. They want medicines to work. But they also want to thrive with fewer side effects and day-to-day disruptions. If efficacy is a top priority in cancer ...
Seeking Alpha

Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer

Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death Results from the LIBRETTO-432 trial build on ...
Morningstar

CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting

CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting CALQUENCE plus venetoclax ...